Gastrointestinal carcinoid tumors

M. J. Varas-Lorenzo, F. Muñoz-Agel, J. C. Espinós-Pérez and M. Bardají-Bofill

Unit of Endoscopy. Centro Médico Teknon. Barcelona, Spain

ABSTRACT

Objective: carcinoid tumors (CTs) represent the commonest neuroendocrine tumors.

Those in the gastrointestinal tract are diagnosed in surgical specimens, clinically, and using imaging techniques (endoscopy, echoendoscopy, CT, Octreoscan, etc.).

The goal of this retrospective study was to review a personal series of gastrointestinal carcinoid tumors, and to compare it to those in the literature.

Patients and methods: the medical records of 40 Caucasian patients with 50 gastrointestinal carcinoid tumors (including multiple cases) who were seen for a period of 16 years (1994-2009) were reviewed.

Results: mean age at presentation was 52 years, 50% were females, and mean tumor size was 9.9 mm. Most were gastroduodenal (42.5%) or rectal (30%), and were treated endoscopically. Metastases and carcinoid syndrome (CS) were seen in 5% of patients. Survival at study endpoint was 85%.

Conclusions: age and gender were consistent with the literature. There was an increase in gastroduodenal (multifocal) and rectal carcinoids, likely because the series was essentially endoscopical in nature (bias). There was a lower rate of CS and higher survival, likely due to earlier diagnosis and treatment.

Key words: Gastrointestinal carcinoid tumors. Neuroendocrine tumors. Carcinoid syndrome.

INTRODUCTION

Carcinoid tumors (CTs) were described more than 100 years ago by Oberndorfer (1,2). MacDonald (1) found 0.02% carcinoids in surgical cases, and 1% in necropsies.

Received: 29-10-09.
Accepted: 25-02-10.

Correspondence: M. J. Varas Lorenzo. Centro Médico Teknon. C/ Marquesa de Vilallonga, 12. 08017 Barcelona, Spain. e-mail: varas@dr.teknon.es

The incidence of carcinoid tumors has increased over time from 0.32/100,000 population and year (3) in the only community-based study available to 1-2 cases/100,000/year (4,5), and then further to 4.4/100,000/year (6,7); the rate in surgical specimens and necropsies was 8.4/100,000/year in Sweden during a 12-year period of time (8). The one study in our country (9) points out an incidence of 0.7/100,000 population/year for all CTs (0.125% in necropsies).

CTs occur twice as much in Afro-American than in Caucasian patients (10). Gender distribution is similar,
slightly higher in females for malignant carcinoids at any age, but predominating in the sixth decade of life.

Gastrointestinal carcinoids used to predominate (74%) over bronchopulmonary ones (25%), 67.5 versus 25.3% (6) (Table I), but this proportion has been inverted of late (20 versus 72%) (11). Differences are due to the varying series and studies: clinical, surgical, or necropsy-derived.

Appendicular (60%) (1, 9), rectal, and ileal (4, 12) CTs were most common. Intestinal CTs represent 1% of gastrointestinal tract malignancies.

Another register shows an increase in pulmonary, gastrointestinal, and intestinal CTs, and a decrease in appendicular CTs (5).

Reviews have been performed (12) and series have been reported for gastric, duodenal, intestinal, appendicular, rectal, etc., carcinoids.

These tumors may give rise to a typical carcinoid syndrome (CS) (flushing, bronchoconstriction and watery diarrhoea) or an atypical one (CS-like).

### OBJECTIVE

The goal of this retrospective study was to review a personal series of gastrointestinal carcinoid tumors, and to compare it to an updated review on this topic.

### PATIENTS AND METHODS

Forty Caucasian patients with over 50 gastrointestinal carcinoid tumors seen during 16 years were reviewed (1994-2009); several subjects had multifocal tumors and one was a multiple site case: a patient with MEN-1 had several gastric and one retroperitoneal carcinoids. Only one had a typical carcinoid syndrome, and one had an atypical carcinoid syndrome.

Bias: the series was mainly based on endoscopy and echoendoscopy (EUS) cases, therefore the number of gastroduodenal and colorectal carcinoids is higher than that of appendicular (appendicitis) or intestinal (subocclusion) ones, whose frequency is higher in surgical series.

Among all 40 patients, 25 gastroduodenal and colorectal tumors were treated endoscopically, and 16 patients with 21 CTs underwent EUS-assisted endoscopic resection once metastatic disease had been ruled out using CT scans and Octreoscan.

Demographic parameters (race, age, sex, etc.), variables related to endoscopic and echoendoscopic tumor characteristics (size, morphology, etc.), lesion location, clinical manifestations, management, and survival at review were all analyzed.

The statistical analysis was carried out using the SPSS 11.5 for Windows software.

### RESULTS

Mean age at presentation was 52 years (range: 13-81 years). Sex: 20 M and 20 F (50%). All patients were Caucasian.

CT location: 0 esophagus, 14 stomach (35%), 3 duodenum (7.5%), 3 intestine (7.5 %), 5 appendix (12.5%), 1 colon (2.5%), 12 rectum (30 %), 1 pancreas, and 1 liver (2.5%).

Multifocal in one organ: 10 in stomach (25%), 1 in duodenum, 1 in intestine (2.5%).

Multiple sites: one case of MEN-1 with multifocal gastric tumors and one retroperitoneal carcinoid; it was managed with somatostatin analogues.

Mean size of lesions: 9.9 mm (range: 2-35 mm).

Endoscopic, echoendoscopy (EUS) and CT scans were the determinant diagnostic modalities.

Treatment: polypectomy (14 cases), band-assisted mucosectomy (6 cases), transanal endoscopic micro-surgery (TEM) (2 cases), appendectomy (5 cases), surgical resection (3 cases), somatostatin (3 cases), and chemotherapy (2 cases). None was treated with growth factor inhibitors.

Endoscopic management was used for 25 gastroduodenal and colorectal tumors, and 16 patients with 21 CTs underwent EUS-assisted endoscopic resection. This series is the subject of a different report.

Metastases and CS: 2/40 (5%).

Survival: 34/40 (85%).

### DISCUSSION

Tumors in the esophagus (0.1%) (11), bile ducts, papilla, and pancreas are anecdotal findings (12) (Tables I and II).

One of our cases involved the pancreas and had liver metastases, had been surgically confirmed, and had a carcinoid-like syndrome that was treated with somatostatin analogues (13).
Gastric C Ts amount to less than 1% of gastric neoplasms, and represented 2-4% of all carcinoids (4,5), but their rate has increased to almost 12%.

Up to more than 70% of cases (12,14-19) are associated with type-A chronic atrophic gastritis (ACAG) or pernicious anemia (gastric C Ts, type 1). They are usually smaller than 1 cm and multifocal in 50%. Hypergastrinemia plays a fundamental role (14,15), so chronic therapy with Sandostatin is appropriate.

Around 5-10% of cases (gastric C Ts, type 2) are associated with Zollinger-Ellison syndrome (ZES) in the setting of MEN-1 under genetic influence. Treatment and prognosis are similar to those associated with ACAG.

Approximately 15-25% of cases are sporadic (gastric C Ts, type 3), single lesions greater than 1-2 cm, and originate metastases in over 50% of patients (Ki greater than 2%). They have been associated with an atypical carcinoid syndrome induced by histamine.

When greater than 2 cm these tumors are usually fatal (16). In our series no gastric CT was greater than 2 cm, and most were treated endoscopically (Table III).

### Table II. Historical series and current endoscopic series

<table>
<thead>
<tr>
<th>Surgical series (26)</th>
<th>Mixed series (clinical-surgical) (28)</th>
<th>Endoscopic series</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT (CS)</td>
<td>14 (2) 14%</td>
<td>11 (1) 66 (5) 41 (2)</td>
</tr>
<tr>
<td>GI tract</td>
<td>14 (2) 14%</td>
<td>10 (1) 10% 66 (5) 7.6 (2) 5%</td>
</tr>
<tr>
<td>Rectum</td>
<td></td>
<td>12 (30%)</td>
</tr>
<tr>
<td>Appendix</td>
<td>11 (78.6%) 4 (40%) 25 (37.5%) 5 (12.5%)</td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>0 1</td>
<td>1 (2.5%) 3 (7.5%)</td>
</tr>
<tr>
<td>Ileum</td>
<td>2 3</td>
<td>3 (7.5%)</td>
</tr>
<tr>
<td>Duodenum</td>
<td>1 1</td>
<td>3 (7.5%)</td>
</tr>
<tr>
<td>Stomach</td>
<td>0 1</td>
<td>14 (35%)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>2 (5%)</td>
</tr>
<tr>
<td>(pancreas, etc.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CS: carcinoid syndrome: flushing and watery diarrhea. Its frequency in the literature is lower than 10% of all CTs. Soga (30): 7.7%. Current series: 2/40 (5%).

Gastric C Ts amount to less than 1% of gastric neoplasms, and represented 2-4% of all carcinoids (4,5), but their rate has increased to almost 12%.

Up to more than 70% of cases (12,14-19) are associated with type-A chronic atrophic gastritis (ACAG) or pernicious anemia (gastric C Ts, type 1). They are usually smaller than 1 cm and multifocal in 50%. Hypergastrinemia plays a fundamental role (14,15), so chronic therapy with Sandostatin is appropriate.

Around 5-10% of cases (gastric C Ts, type 2) are associated with Zollinger-Ellison syndrome (ZES) in the setting of MEN-1 under genetic influence. Treatment and prognosis are similar to those associated with ACAG.

Approximately 15-25% of cases are sporadic (gastric C Ts, type 3), single lesions greater than 1-2 cm, and originate metastases in over 50% of patients (Ki greater than 2%). They have been associated with an atypical carcinoid syndrome induced by histamine.

When greater than 2 cm these tumors are usually fatal (16). In our series no gastric CT was greater than 20 mm, and most were treated endoscopically (Table III).

### Table III. Series and reviews of gastric carcinoids

<table>
<thead>
<tr>
<th>Author &amp; year</th>
<th>No.</th>
<th>Sex</th>
<th>Age X</th>
<th>Multiple</th>
<th>H</th>
<th>Metastasis</th>
<th>CS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanders 1964</td>
<td>86</td>
<td>c</td>
<td>28</td>
<td>--</td>
<td></td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Gough 1994</td>
<td>36</td>
<td>M</td>
<td>58%</td>
<td>42%</td>
<td>50%</td>
<td>33%</td>
<td>11%</td>
</tr>
<tr>
<td>Thomas 1994</td>
<td>104</td>
<td>M</td>
<td>55%</td>
<td>61%</td>
<td>42%</td>
<td>10%</td>
<td>0%</td>
</tr>
<tr>
<td>X: 19 mm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modlin 1995</td>
<td>16</td>
<td>M</td>
<td>50%</td>
<td>66%</td>
<td>50%</td>
<td>63%</td>
<td>GCA 0%</td>
</tr>
<tr>
<td>X: 7.9 mm</td>
<td>13</td>
<td>M</td>
<td>38%</td>
<td>50%</td>
<td>69%</td>
<td>61%</td>
<td>7.7% 0%</td>
</tr>
<tr>
<td>Vara 1997</td>
<td>265</td>
<td>c</td>
<td>64%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased from 0.3 to 0.54%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modlin 2003</td>
<td>562</td>
<td>c</td>
<td>62 a.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased from 0.3 to 1.77%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival at 5 years 51-63%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mulkeen (44): review</td>
<td>64% M</td>
<td></td>
<td>M:F ratio 1.2 vs. 1.71 for gastric cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Massironi (45): review, classification, management and treatment with somatostatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Their rate and incidence have increased (19), which our series also seems to corroborate.

Duodenal C Ts are usually small, less than 1 cm in size (our cases were equal to or smaller than 5 mm) and located in the bulb (20). In the most extensive series (21) with 24 cases, 89% were smaller than 2 cm, and 85% were confined to the mucosa and submucosa, with a survival rate of 100% at nearly 4 years.

Intestinal tumors represent 1% of gastrointestinal tract malignancies (22), with an incidence of 0.7 in males and 0.6/100,000 in women (22); they are usually located in the ileum and are multifocal or multisite, induce metastasis in lymph nodes and the liver (second only to right colon tumors in metastasis production), and result in typical carcinoid syndrome (flushing and watery diarrhea) because of serotonin (5-HIAA), substance P, etc., in 5-7% of patients.

Among the three cases in our series two were single lesions and one was multifocal (subocclusion); none had liver metastasis, and both responded well to surgery (Fig. 1).

They induce bleeding, mesenteric fibrosis, and occlusion leading to intestinal resection.

Malignant carcinoid tumors have a survival rate of 65% at 5 years (12). In a recent study of 3,911 intestinal carcinoids during 30 years (23) 5-year survival was 63%, 74% for localized C Ts, 72% for C Ts with regional metastasis, and 43% for those with distant metastases. This register claims that intestinal C Ts are most common (21% of all gastrointestinal C Ts), and their rate is increasing mainly in women and black patients.

Appendicular C Ts are diagnosed in the fourth or fifth decade of life (12,24); in younger patients they are found in appendectomy specimens after acute appendicitis (25); they are more common in women than in men (25). Four of the 5 patients in our series were females.

Tumor size is the most significant prognosis factor –95% are smaller than 2 cm and appendectomy suffices.

![Fig. 1. Carcinoid tumor (courtesy Dra. Cristina Durán).](image)
One third are greater than 2 cm and present with metastasis, which requires right colectomy (24, 25).

Survival at 5 years is 94% when the disease is confined to the appendix (5), 85% when regional metastases exist, and 34% when distant metastases are present (even liver metastases, which may result in carcinoid syndrome).

Among gastrointestinal CTs appendicular tumors are most common, with rates of 44% (4), 60% (1), 66% (9), 78% (26), and 73% (27).

Colonic CTs are rare and big, represent less than 1% of all colonic tumors, and fewer than 5% induce CS. Five-year survival is 70% when local (5), 44% when regional metastases are present, and 20% for cases with distant metastases.

In our series only one colonic carcinoid was found, which was 30 mm in size and had no metastasis.

Rectal carcinoids represent 1.8% of rectal neoplasms (4) and up to 15-20% of gastrointestinal carcinoids (29, 30), and are more common in the sixth decade of life (5). Around 50% are asymptomatic and represent chance findings during routine colonoscopies in the USA. Most common symptoms include anorectal complaints (29).

Survival after 5 years is 81, 47, and 18%, respectively (5) in the USA. Survival was 85% in Japan (30).

Those smaller than 1 cm are treated with local excision because of their early diagnosis (30). Tumors greater than 2 cm represent surgical cases (low anterior resection or abdominoperineal resection depending on their level in the rectum), since these lesions have metastasis in 83% of cases and muscularis propria infiltration in 88% of patients (31).

The management and therapy of tumors 1-2 cm in size is controversial, but most will benefit from local treatment, with polypectomy versus band-assisted resection (32-34). Most of our cases were treated with polypectomy, band-assisted mucosectomy, and TEM.

In our series, likely because of its bias, gastric and rectal lesions were most common, and were managed with endoscopic therapy (polypectomy and bands, mainly) (35) (Fig. 2).

The incidence of gastrointestinal (23, 36) and rectal CTs is increasing when compared to that seen 25 years ago, around 0.4/100,000/year (3, 35); it is probably above 4 cases/100,000 population/year, whereas in the USA the incidence of bronchopulmonary CTs was 1.57/100,000 in 2003 (37). Total CT incidence is higher than 5 cases/100,000/year, and digestive lesions, mainly intestinal tumors, remain preponderant (38-41); the prevalence and incidence of rectal CTs (42, 43) and gastric CTs (44-46) is also increasing. Polish authors (43) analyzed over 50,000 colonoscopies in a screening program for colorectal cancer, and found 25 carcinoids (prevalence: 0.05%) in 24 patients with a mean age of 54 years; maximum tumor size was 10 mm (mean: 6 mm). The increase in gastric CTs may possibly result from screening with gastroscopy and biopsies, as well as from a greater use of immunocytochemistry (positivity for chromogranin and synaptophysin is pathognomonic for carcinoid) (46).

The prognosis of CTs depends on their size (1 cm), the presence or absence of metastasis, and the development of CS (less than 10%). Tumors greater than 1 cm metastasize to the liver in 58% of cases, and show a 5-year survival rate of 43% in a classic series of 156 cases – 47 appendicular (30%) and 41% multiples lesions (35).

The Brazilian registry (11) shows a 5-year survival rate around 70%, and 10-year survival at 50%; at the time of analysis 30% of patients were still alive, and 46% of these had no evidence of disease. Current survival in our series is 85%.

Survival for rectal and gastric CTs has increased over 20% in late reviews, probably due to earlier diagnosis (endoscopy, biopsies, echoendoscopy, CT scanning, and Octreoscan) and treatment (42, 46).

Somatostatin analogues may also have probably represented an advance in the management of CTs, particularly of gastric tumors, types 1 and 2 (46).

CONCLUSIONS

In our series patient age and gender (Caucasians) was similar to that described in the literature. The most common location was the stomach.

Overall incidence is probably increasing; regarding historical series, the percentage of gastroduodenal (many of them multifocal) and rectal CTs have increased likely due to the use of endoscopy, and because the initial historical series was predominantly surgical in nature (appendicular tumors predominated). The percentage of intestinal and appendicular carcinoids has decreased in contrast with literature reviews, but there is probably a bias since our series was based on endoscopy and echoendoscopy procedures. Most gastroduodenal and rectal CTs were treated endoscopically.
CS has decreased likely because of earlier CT diagnosis and treatment, and survival has slightly increased as a result of novel therapies.

REFERENCES

42. Scherhui B. Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy 2009; 41: 162-5.